About
Peptibody, Monoclonal Antibody, Cell Therapy
Areas of Focus
Categories
Biologics & BiopharmaceuticalStem Cell & Cellular TherapyAntibodySan Diego & Southern California
Clinical Trials (11)
View allTotal Trials
11
As Lead Sponsor
8
As Collaborator
3
Total Enrollment
386
By Phase
PHASE1: 4PHASE1/PHASE2: 3PHASE2: 2
By Status
COMPLETED: 4TERMINATED: 3NO_LONGER_AVAILABLE: 2WITHDRAWN: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline9 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06429800Lead Sponsor
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus
PHASE1Withdrawn
Started: Apr 16, 2025 · Completed: Apr 16, 2025
NCT06256484Lead Sponsor
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
PHASE1Terminated
1 participants
Started: Sep 6, 2024 · Completed: Mar 30, 2025
NCT04577326Collaborator
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
PHASE1Active, not recruiting
14 participants
Started: Sep 30, 2020 · Completed: Sep 30, 2026
NCT03769467Lead Sponsor
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
PHASE1/PHASE2Terminated
12 participants
Started: Feb 19, 2019 · Completed: Aug 19, 2021
NCT03283826Lead Sponsor
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
PHASE1/PHASE2Terminated
134 participants
Started: Oct 19, 2017 · Completed: Jan 17, 2024
Locations (1)
Headquarters
Thousand Oaks, CA, United States
Map
Loading map...